Market Overview

Theravance Confirms Favorable Ruling from FDA Panel on VIBATIV

Related THRX
Glaxosmithkline, Theravance Intend to File Relvar Ellipta for COPD in Japan
Theravance Just Lost Its Catalyst

Theravance Inc. (NASDAQ: THRX) today announced a favorable outcome of the Anti-Infective Drugs Advisory Committee (AIDAC) of the U.S. FDA meeting on VIBATIV(R) (telavancin) for the treatment of nosocomial pneumonia (NP) due to susceptible isolates of Gram-positive microorganisms.

Posted-In: News FDA


Related Articles (THRX)

View Comments and Join the Discussion!

Get Benzinga's Newsletters